Thymosin Alpha-1

Thymosin Alpha-1

Thymosin Alpha-1

Thymosin alpha 1 (TA-1) est naturaliter occurrens 28-amino acido peptide perstringitur in thymo.

SKU: 198889 Categoria:
Participes tui amoris

Thymosin alpha 1 (TA-1) est naturaliter occurrens 28-amino acidum peptide summatim intra thymus. Serviens ut endogenous immunomodulator, auget T cellula mediata immunis respondeo; machinae specificae differentiam et maturationem cellae T involvunt progenitoris cellulae, activation of * cellulis dendritic et naturalis interfectorem cellulae, una cum variis formis cytokini mediatae inflammationis.

Cum inventione, agnitio comprehensiva Thymosin alpha 1 possessiones immunes amplificandae constitutae sunt.

Sequentia

Ac-Ser-Asp- Ala-Ala-Val-Asp-Thr-Ser-Glu-Ile Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

CAS Number

62304-98-7

Formulae hypotheticae

C129H215N33O55

M. Pondus

3108.28

Investigatio Thymosin Alpha-1

1.Mechanismi immunes et functiones

Ut molecula pleiotropica immunomodulatoria, prima actio pharmacologicae thymosin alpha-1 est restitutio et amplificatio functionis immunis – immunitatis ens clavem status intendit corrigere.

Agonist agens pro Vectigal sicut receptor (TLR) 9 et TLR-II in cellulis dendritic (professio antigen-praesens cellulas), Thymosin alpha 1 incitat adaptivam immunes respondeo; viral, bacterial, Infectiones fungales et cancer omnes potentiale scuta harum responsionum.

Augetur etiam immunitas humoralis. Elevatio gradus plures cytokines (II, II, II, IFNs' esse primum exempla) est alius effectus amet.

Stimulans T productio anticorporis cellae dependens est causa saepe data pro proprietatibus adjuvantibus.

Lata spectrum biologicum actiones, antitumor inter eos, sunt currently quaeruntur.

2.Fusce Applications et Therapeutica Potentia
(1)Curatio De Viris Illustribus Infectiones

Orci probationes salutem et efficaciam thymosin alpha . aestimarunt 1 in chronicis Hepatitis B *(HBV) aegris. Promotio alvi viralis et restitutio functionis hepatis sequitur ex certa responsione T-cell contra HBV ..

Compositum illic cum interferone pegylato efficax est hepatitis C; ipsum thymosin vel conjunctionem cum interfe, manet viable curatio optio.

Recta agendi antivirales thymosin e primitiva linea curatio relegata, sed effectus immunes augendi thymosin alpha 1 permanere amet pertinet.

(2)Tumor Inhibiting Augmentum

Multiplex studiis adhibitis applicationes ad thymosin alpha-1 in aegris metastaticis polliciti sunt melanoma, caput et collum cancer, pulmonis cancer, pectus cancer, et hepatocellulare carcinoma.

Lorem adiective usus est, alloquitur chemotherapy effecerunt immunosuppression, primaria immunitatis, et variae formae immunosuppressive civitatibus.

Combining thymosin alpha-I cum vel chemotherapy vel rectitudo ostendit melius salvos rates; pulmonis cellula non-parva cancer (plerumque omnibus pulmonis carcinomata) esse primum exemplum, pauper chemosensitivity cum una e clavis provocat in hoc morbo.

(3)Curatio Sepsis

Thymosin alpha-1 adhibitum est in curatione periodi immunosuppressive sepsis.

Tum numerum et munus lymphocytarum restituens – T cellulae arx – expectat ut novis statu paralysin immune.

Derelinquens initial infectio, reducendo subsequent secundarium contagione, et deploratio melioris utilitates demonstrabiles sunt huius illic.

Orci studiis confirmaverunt applicationes promittentes, solus aut cum aliis medicamentis.

(4)Ut Vaccinum Adjuvant

Vaccinum adjuvans est ubi thymosin alpha-1 monstrat nonnullos effectus ejus constantissimos et pretiosos.

Fortis cellulares responsiones immunes necessariae sunt ad praecavendum vel curationem multorum morborum; tuberculosis, SCDI, et cancer curationis vaccinum esse insignes exempla.

Influenza vaccina (maxime senes) sunt currently uti hoc adjuvant, Cum positivum orci eventus.

(5)Compositum Therapy HIV cum aliis medicamentis

Combining thymosin alpha-I with interfe-α1 et zidovudine munus auget immune.

CD4+ comites incremento, Viral onus decrescit et orci statum HIV aegris melius.

Diu terminus administrationis thymosin alpha-1 alta-dosis significat accessum magni momenti immunomodulatoris.

Thymosin alpha-1 remanet immunomodulator vere pleiotropicus cum potential therapeutica substantiali.

COA

HPLC

MS

(1).Poo, J. L.; Sanchez-Avila, F.; Kershenobich, D.; GarcÍA‐Samper, Decimus.; Gongora, J.; Uribe, M. Triple combination of thymalfasin, peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24‐week interim results of a pilot study J. Gastroenterol. Hepatol. 2004.

(2).Romani, L.; Bistoni, F.; Gaziano, R.; Bozza, S .; Montagnoli, C.; Perruccio, K.; Pitzurra, L.; Bellocchio, S .; Velardi, A.; Rasi, G.; di Francesco, P .; Garaci, E. Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling Sanguis 2004,4232-4239.

(3).Tuthill, C.; Rios, Et ego.; De Rosa, A.; Camerini, R. Thymosin α1 continues to show promise as an enhancer for vaccine response Ann. N.Y. Acad. Sci. 2012,21-27.

(4).Naylor, P. H.; Quadrini, K.; Garaci, Ej.; Rasi, G.; Hadden, J. W. Immunopharmacology of Thymosin α1 and Cytokine Synergy Ann. N.Y. Acad. Sci. 2007,235-244.

(5).Sherman, K. E. Thymosin α 1 for treatment of hepatitis C virus: promise and proof Ann. N.Y. Acad. Sci. 2010,136-140.

(6).Eckert, K.; Schmitt, M.; Garbin, F.; Wahn, U.; Maurer, H. R. Thymosin α1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies: Preliminary results Int. J. Immunopharmacol 1994,1019-1025.

(7).Costantini, C.; Bellet, M. M.; Pariano, M.; Renga, G.; Stincardini, C.; Goldstein, A. L.; Garaci, Ej.; Romani, L. A Reappraisal of Thymosin Alpha1 in Cancer Therapy Front. Oncol. 2019.

(8).Li, C.; Bo, L.; Liu, Q^.; Jin, F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis Int. J. Infect. Dis. 2015,90-96.

(9).Panatto, D.; Amicizia, D.; Lai, P. L.; Camerini, R.; Rosa, A. D.; Gasparini, R. Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review. Journal of Preventive Medicine and Hygiene. J. Prev. cum. Hyg. 2015.

(10).Matteucci, C.; Grelli, S .; Balestrieri, Ej.; Minutolo, A.; Argaw-Denboba, A.; Macchi, B ad.; Sinibaldi-Vallebona, P .; Perno, C. F.; Mastino, A.; Garaci, E. Thymosin Alpha 1 and HIV-1: Recent Advances and Future Perspectives Future Microbiol. 2017,141-155.

specificatio

10 mg, 5 mg

Home Investigatio whatsapp Officia Productum